Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of Inecalcitol in patients with chronic lymphocytic leukaemia

Next Previous
X
Search
Trial Profile

Phase III trial of Inecalcitol in patients with chronic lymphocytic leukaemia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inecalcitol (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors ATON

    • Most Recent Events

    • 12 Feb 2014 New trial record
    • 28 Jan 2014 Inecalcitrol has been designated as an orphan drug for chronic lymphocytic leukaemia in Europe, giving access to the COMP Protocol Assistance procedure to design this phase III study, according to a Hybrigenics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top